Next Article in Journal
Serum Metabolomics Uncovers the Mechanisms of Inulin in Preventing Non-Alcoholic Fatty Liver Disease
Previous Article in Journal
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 7
10.3390/ph17070892
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceuticals 2024, 17(2), 247.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Benington et al. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247

by
Leah Benington
1,
Jingxin Mo
2,3,
Mingxin Li
2,4,
Gunesh Rajan
5,6,
Cornelia Locher
1 and
Lee Yong Lim
1,*
1
Division of Pharmacy, School of Allied Health, University of Western Australia, Perth, WA 6009, Australia
2
Neuroscience Laboratory, The Affiliated Hospital of Guilin Medical University, Guilin 541001, China
3
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia
4
Department of Pharmacy, Tangshan Central Hospital, Tangshan 063000, China
5
Otolaryngology, Head & Neck Surgery, Division of Surgery, Medical School, University of Western Australia, Perth, WA 6009, Australia
6
Department of Otolaryngology, Head & Neck Surgery, Luzerner Kantonsspital, 6000 Luzern, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(7), 892; https://doi.org/10.3390/ph17070892
Submission received: 28 June 2024 / Accepted: 1 July 2024 / Published: 5 July 2024
Browse Figures
Versions Notes
In the original publication [1], there was a mistake in Figure 5. which was published. The image for the FGF-2 solution in vehicle 5 was mislabeled and required a replacement. A corrected version of Figure 5 appears below. The authors confirm that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Benington, L.; Mo, J.; Li, M.; Rajan, G.; Locher, C.; Lim, L.Y. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00892 g005aPharmaceuticals 17 00892 g005b
Figure 5. Fluorescence micrographs showing chemotactic migration of human dermal fibroblast cells to the basal surface of a transwell membrane in response to FGF-2. Cells seeded on the apical transwell membrane were exposed to FGF-2 solutions or blank vehicles added to the basolateral chamber. Samples comprise blank vehicles or FGF-2 (50 ng/mL in the vehicle) in the vehicles: 1 (water only), 2 (methylcellulose (MC) 0.05% w/v), 3 (alanine 20 mM), 4 (human serum albumin (HSA) 1 mg/mL), 5 (MC 0.05% w/v and alanine 20 mM) and 6 (MC 0.05% w/v and HSA 1 mg/mL). Magnification: 200×, scale bar = 100 µm.
Figure 5. Fluorescence micrographs showing chemotactic migration of human dermal fibroblast cells to the basal surface of a transwell membrane in response to FGF-2. Cells seeded on the apical transwell membrane were exposed to FGF-2 solutions or blank vehicles added to the basolateral chamber. Samples comprise blank vehicles or FGF-2 (50 ng/mL in the vehicle) in the vehicles: 1 (water only), 2 (methylcellulose (MC) 0.05% w/v), 3 (alanine 20 mM), 4 (human serum albumin (HSA) 1 mg/mL), 5 (MC 0.05% w/v and alanine 20 mM) and 6 (MC 0.05% w/v and HSA 1 mg/mL). Magnification: 200×, scale bar = 100 µm.
Pharmaceuticals 17 00892 g005aPharmaceuticals 17 00892 g005b
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Benington, L.; Mo, J.; Li, M.; Rajan, G.; Locher, C.; Lim, L.Y. Correction: Benington et al. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247. Pharmaceuticals 2024, 17, 892. https://doi.org/10.3390/ph17070892

AMA Style

Benington L, Mo J, Li M, Rajan G, Locher C, Lim LY. Correction: Benington et al. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247. Pharmaceuticals. 2024; 17(7):892. https://doi.org/10.3390/ph17070892

Chicago/Turabian Style

Benington, Leah, Jingxin Mo, Mingxin Li, Gunesh Rajan, Cornelia Locher, and Lee Yong Lim. 2024. "Correction: Benington et al. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247" Pharmaceuticals 17, no. 7: 892. https://doi.org/10.3390/ph17070892

APA Style

Benington, L., Mo, J., Li, M., Rajan, G., Locher, C., & Lim, L. Y. (2024). Correction: Benington et al. In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions. Pharmaceuticals 2024, 17, 247. Pharmaceuticals, 17(7), 892. https://doi.org/10.3390/ph17070892

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop